Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy

References

• Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 1989; 63: 364–367
   PubMed Web of Science ®Google Scholar
• Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Result of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358–363
   PubMed Web of Science ®Google Scholar
• Jayne DG, Fook S, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545–1550
   PubMed Web of Science ®Google Scholar
• Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy for advanced gastric cancer: Results of a prospective randomized trial. World J Surg 2001; 25: 985–990
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly F, Sugarbaker PH. New perspectives in the management of colorectal cancer: What about peritoneal carcinomatosis?. Scand J Surg 2003; 92: 178–179
   PubMedGoogle Scholar
• Verwaal VJ, Van Ruth S, de Bree E, Van Sloothen GW, Van Tinteren H, Boot H, Zoetmulder FAN. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737–3743
   PubMed Web of Science ®Google Scholar
• Link KH, Roitman M, Holtappels M, Runnebaum I, Urbanzyk H, Leder G, Staib L. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 2003; 12: 865–872
   PubMedGoogle Scholar
• Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Peritoneal Carcinomatosis: Principles of Management, PH Sugarbaker. Kluwer, Boston 1996; 79–100
   Google Scholar
• Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer Metastasis Rev 2003; 22: 465–472
   PubMedGoogle Scholar
• Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29–42
   PubMed Web of Science ®Google Scholar
• Weiss L. Metastatic inefficiency: Causes and consequences. Cancer Rev 1986; 3: 1–24
   Google Scholar
• Schott A, Vogel I, Krueger U, Kalthoff H, Schreiber HW, Schmiegel W, Henne-Bruns D, Kremer B, Juhl H. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 1998; 227: 372–379
   PubMed Web of Science ®Google Scholar
• Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: Analysis of experimental data in the rat. Am J Physiol 1985; 248: 413–424
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Eng J Med 1996; 335: 1950–1955
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy BN, Alberts DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001–1007
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34–43
   PubMed Web of Science ®Google Scholar
• Engelhardt R. Hyperthermia and drugs. Recent Results Cancer Res 1987; 104: 136–203
   PubMedGoogle Scholar
• Dahl O. Interaction of hyperthermia and chemotherapy. Recent Results Cancer Res 1988; 107: 157–169
   PubMedGoogle Scholar
• Meyer JL. Kapp DS, Fessenden P, Hahn GH. Hyperthermic oncology: Current biology, physics and clinical results. Pharmac Ther 1989; 42: 251–288
   PubMed Web of Science ®Google Scholar
• Urano M, Kuroda M, Nishimura Y. Invited review for the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999; 15: 79–107
   PubMed Web of Science ®Google Scholar
• Marmor JB, Kozak D, Hahn GM. Effects of systemically administered bleomycin or adriamycin with local hyperthermia on primary tumor and lung metastases. Cancer Treat Rep 1979; 63: 1279–1290
   PubMedGoogle Scholar
• Mella O, Dahl O. Timing of combined hyperthermia and 1,3-bis(2-chloroethyl)-1-nitrosurea or cis-diamminedichloroplatinum in BD IX rats with BT4A tumours. Anticancer Res 1985; 5: 259–264
   PubMed Web of Science ®Google Scholar
• Dahl O, Mella O. Effect of timing and sequence of hyperthermia and cyclophosphamide on a neurogenic rat tumor (BT4A) in vivo. Cancer 1983; 52: 983–987
   PubMed Web of Science ®Google Scholar
• Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH. Docetaxel and hyperthermia: Factors that modify thermal enhancement. J Surg Oncol 2004; 88: 14–20
   PubMed Web of Science ®Google Scholar
• Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH. Optimizing factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. Cancer Chemother Pharmacol 2006; 58: 719–724
   PubMed Web of Science ®Google Scholar
• Los G, Smals OAG, Van Vugt MJH, Van der Vlist M, den Engelse L, McVie JG, Pinedo HM. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992; 52: 1252–1258
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH. Hyperthermic intraperitoneal doxorubicin: Pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998; 41: 147–154
   PubMed Web of Science ®Google Scholar
• Hahn GM, Li GC. Interactions of hyperthermia and drugs: Treatments and probes. Nat Cancer Inst Monogr 1982; 61: 317–323
   PubMedGoogle Scholar
• Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39: 3209–3214
   PubMed Web of Science ®Google Scholar
• Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: Analysis of experimental data in the rat. Am J Physiol 1985; 248: 413–424
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005; 10: 112–122
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol 2005; 92: 142–146
   PubMed Web of Science ®Google Scholar
• Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 1998; 55: 130–138
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Van Tinteren H, Van Ruth S, Zoetmulder FAN. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 2004; 91: 739–746
   PubMed Web of Science ®Google Scholar
• Elias D, Pocard M, Sideris L, Ede C, Ducreux M, Boige V, Lasser P. Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91: 455–456
   PubMed Web of Science ®Google Scholar
• Zylberberg B, Dormont D, Madelenat P, Darai E. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in stage IIIc ovarian epithelial cancer. Eur J Gynaecol Oncol 2004; 25: 327–332
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6: 727–731
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol 2006; 7: 69–76
   PubMed Web of Science ®Google Scholar
• Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O’Brien PC, Van Heerden JA. Pseudomyxoma peritonei: Long-term patient survival with an aggressive regional approach. Ann Surg 1994; 2: 112–119
   Google Scholar
• Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27: 1089–1103
   PubMed Web of Science ®Google Scholar
• Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: An analysis of surgical therapy. Ann Surg 2005; 241: 300–308
   PubMed Web of Science ®Google Scholar
• Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol 2007, 12 Jan [Epub ahead of print]
   Google Scholar
• Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560–4567
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006; 32: 644–647
   PubMed Web of Science ®Google Scholar
• Taub RN, Hesdorffer ME, Keohan ML. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for malignant peritoneal mesothelioma (MPM). J Clin Oncol 2005, (Abstract)
   Google Scholar
• Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras AD, Kusamura S. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006; 13: 229–237
   PubMed Web of Science ®Google Scholar
• Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006; 10: 1561–1567
   Google Scholar
• Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004; 22: 3284–3292
   PubMed Web of Science ®Google Scholar
• Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011–4019
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999; 43(Suppl): S15–S25
   Google Scholar
• Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004; 10: 2727–2730
   PubMed Web of Science ®Google Scholar
• Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol 2007, May 11 [Ep06]
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquivel J, Chang D. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006; 13: 635–644
   PubMed Web of Science ®Google Scholar